The Latest Cardiac and Vascular News
LONDON, Nov. 16, 2023 /PRNewswire/ — Founder and CEO of CardioThrive, Shelley Savage has dedicated her career to saving lives. Her company’s patented invention, the PocketDefib™, has the potential to dramatically reduce the number of deaths caused by SCA (Sudden cardiac arrest) all over…
FORT COLLINS, Colo., Nov. 15, 2023 (GLOBE NEWSWIRE) — Enlitic®, a pioneering force in the realm of medical imaging data management, is gearing up for its participation in the Radiological Society of North America (RSNA) Annual Scientific Assembly and Meeting 2023. Enlitic is entering this year’s meeting with an unwavering […]
Patients undergoing non-invasive treatment show significant improvement in frequency of chest pain, exercise capacity and quality-of-life markers FORT WORTH, Texas, Nov. 15, 2023 /PRNewswire/ — Enhanced External Counterpulsation (EECP®), a non-invasive treatment that increases blood…
Multicenter clinical study showcases how Tenzing® technology is improving neurovascular intervention outcomes SAN MATEO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced compelling results from a multicenter clinical study1 on the […]
CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD. These two trials are part of the registration-enabling Phase 3 LIBerate Pro
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen continues commitment to supporting PAD patients with ongoing…
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 […]
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into […]
Caristo’s AI Technology for Coronary Inflammation Measurement and Risk Assessment Can Transform Risk Stratification and Management of Patients PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ — New research, presented today at the American Heart Association’s Late Breaking Science Sessions, has…
DENVER – November 11, 2023 – Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to […]
